A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
- First Online:
- 354 Downloads
PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine. The current trial was aimed at assessing whether the replacement of E with docetaxel (D) may improve 6 months PFS (PFS6).
Chemo-naive patients with stage III or metastatic PA received P (30 mg/m2 day 1 and 15), G (800 mg/m2 day 1 and 15), and capecitabine (1,250 mg/m2/day days 1–28, without a break) and were randomized to receive either D at 25–30 mg/m2 day 1 and 15 (arm A: PDXG regimen) or E at 30 mg/m2 day 1 and 15 (arm B: PEXG regimen). Cycles were repeated every 28 days for a maximum of 6 months. The Fleming design was used to calculate the sample size on the probability of being PFS6. Assuming P0 = 40% and P1 = 60%, α = 0.05 and β = 0.10; the study was to enroll 52 patients per arm.
Between July 2005 and September 2008, 105 patients were enrolled, stratified by stage and randomized. Patients’ characteristics were (A/B) the following: median age 61/59, PS >70 92/88%, metastatic disease 66/65%. PFS6 was 58%, and median OS was 11 months in both arms. A partial response was observed in 60/37% of patients. Main per cycle G3-4 toxicity was the following: neutropenia 4/13%, thrombocytopenia 2/4%, anemia 4/4%, and fatigue 6/3%.
The inclusion of D instead of E yielded more objective response and less G3-4 neutropenia but did not improve PFS and OS. The present trial confirms the relevant impact on outcome of advanced PA of 4-drug regimens.
KeywordsCapecitabine Chemotherapy Cisplatin Docetaxel Gemcitabine Pancreatic cancer
- 5.Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the Central European cooperative oncology group. J Clin Oncol 25:2212–2217PubMedCrossRefGoogle Scholar
- 7.Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30 min infusion) in patients with pancreatic carcinoma E6201: a trial of the eastern cooperative oncology group. J Clin Oncol 27:3778–3785PubMedCrossRefGoogle Scholar
- 26.Greene FL, Page D, Fleming ID et al (eds) (2002) Exocrine pancreas. In: AJCC cancer staging manual, 6th edn. Springer, New York, pp 157–164Google Scholar
- 31.Lutz MP, Van Cutsem E, Wagener T et al (2005) Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European organisation for research and treatment of cancer gastrointestinal group. J Clin Oncol 23:9250–9256PubMedCrossRefGoogle Scholar
- 35.Boeck S, Hoehler T, Seipelt G et al (2008) Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19:340–347PubMedCrossRefGoogle Scholar
- 36.Conroy T, Desseigne F, Ychou M et al (2010) Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. Proc Am Soc Clin Oncol 28:abstr 4010Google Scholar
- 37.Cantore M, Fiorentini G, Luppi G et al (2004) Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective randomized phase III trial of the Italian society for integrated locoregional therapy in oncology. J Chemother 16:34–39Google Scholar